CancerDrs

Lung Cancer clinical trials in Florida

95 actively recruiting lung cancer trials at 48 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Florida:
  • Bay Pines VA Healthcare System — Bay Pines, Florida
  • Morton Plant Hospital — Clearwater, Florida
  • Halifax Health Cancer Center for Hope - Daytona Beach — Daytona Beach, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Florida:
  • Orlando Health Cancer Institute - Lake Mary — Lake Mary, Florida
  • The Watson Clinic — Lakeland, Florida
  • Health Central — Ocoee, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Florida:
  • Morton Plant Hospital — Clearwater, Florida
  • South Florida Baptist Hospital — Plant City, Florida
  • Saint Anthony's Hospital Cancer Care Center — St. Petersburg, Florida
  • Moffitt Cancer Center-International Plaza — Tampa, Florida
  • Saint Joseph's Hospital/Children's Hospital-Tampa — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Florida:
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • Nicklaus Children's Hospital — Miami, Florida
  • Arnold Palmer Hospital for Children — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Florida:
  • Cancer Care Centers of Brevard, Inc. — Palm Bay, Florida
  • Florida Cancer Affiliates - Panama City — Panama City, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Florida:
  • Boca Raton Regional Hospital — Boca Raton, Florida
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • University of Florida - Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Florida:
  • Millennium Oncology Research Clinic — Hollywood, Florida
  • University of Florida - Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or …

Sponsor: AstraZeneca
NCT ID: NCT06627647
Sites in Florida:
  • Research Site — Bay Pines, Florida
  • Research Site — Fort Lauderdale, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…

Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Florida:
  • Mid Florida Hematology and Oncology Center — Orange City, Florida
  • BRCR Global — Plantation, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Florida:
  • Research Site — Bay Pines, Florida
  • Research Site — Fort Lauderdale, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Florida:
  • Mayo Clinic Florida ( Site 4043) — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. ( Site 4047) — Miami, Florida
  • Mid Florida Hematology and Oncology Center ( Site 0014) — Orange City, Florida
  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013) — Orlando, Florida
  • Moffitt Cancer Center ( Site 0078) — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Florida:
  • Research Site — Clermont, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Miami Beach, Florida
  • Research Site — Orange City, Florida
  • Research Site — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Florida:
  • Florida Cancer Specialists - SOUTH - SCRI - PPDS — Fort Myers, Florida
  • University of Florida Health at Shands — Gainesville, Florida
  • BioResearch Partner — Hialeah, Florida
  • Memorial Healthcare System - Memorial Regional Hospital — Hollywood, Florida
  • Sylvester Comprehensive Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Florida:
  • The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) — Fort Lauderdale, Florida
  • Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Florida:
  • Florida Oncology and Hematology — Fort Myers, Florida
  • Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
  • Orlando Health Cancer Institute — Kissimmee, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Florida:
  • Mayo Clinic Hospital Jacksonville /ID# 254688 — Jacksonville, Florida
  • Ocala Oncology Florida Cancer Affiliates - Main /ID# 234228 — Ocala, Florida
  • BRCR Medical Center Inc /ID# 262344 — Tamarac, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Florida:
  • University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
  • Memorial Hospital West — Pembroke Pines, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Local Institution - 0477 — Tamarac, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Florida:
  • Research Site — Fort Myers, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — St. Petersburg, Florida
  • Research Site — Tampa, Florida
  • Research Site — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…

Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in Florida:
  • Research Site — Jacksonville, Florida
  • Research Site — Orlando, Florida
  • Research Site — Saint Augustine, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Sites in Florida:
  • Florida Cancer Specialists & Research Institute - South — Fort Myers, Florida
  • BRCR Global — Plantation, Florida
  • Cancer Care Centers of Breevard — Rockledge, Florida
  • Florida Cancer Specialists & Research Institute - North — St. Petersburg, Florida
  • Cleveland Clinic Martin North — Stuart, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Florida:
  • Research Site — Bay Pines, Florida
  • Research Site — Clearwater, Florida
  • Research Site — Gainesville, Florida
  • Research Site — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Florida:
  • Zai Lab Site 02045 — Clermont, Florida
  • Zai Lab Site 02031 — Orange City, Florida
  • Zai Lab Site 02020 — Rockledge, Florida
  • Zai Lab Site 02026 — Sarasota, Florida
  • Zai Lab Site 02052 — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in Florida:
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center — Miami, Florida
  • AdventHealth Orlando, Cancer Institute — Orlando, Florida
  • H. Lee Moffitt Cancer Center and Research Institute, Inc — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung…

Sponsor: Bayer
NCT ID: NCT06452277
Sites in Florida:
  • The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street — Fort Lauderdale, Florida
  • Memorial Cancer Institute at Miramar — Miramar, Florida
  • AdventHealth Cancer Institute Orlando — Orlando, Florida
  • Moffitt Cancer Center - Magnolia Campus — Tampa, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →

Showing 25 of 95 trials with sites in Florida. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10